Savara Inc (SVRA)

03:15 AM

FDA Extends Review Period for Savara's Molgramostim BLA in Autoimmune PAP - National Today

03:15 AM

Apr 15, 2026

SVRA stock slips post-market after FDA delays decision on pulmonary therapy - MSN

Apr 15, 2026

Apr 15, 2026

FDA extends review of Savara’s molgramostim application - Investing.com

Apr 15, 2026

Apr 15, 2026

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire

Apr 15, 2026

Apr 15, 2026

SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy - Stocktwits

Apr 15, 2026

Apr 15, 2026

Savara to present molgramostim data at ATS conference in May - Investing.com

Apr 15, 2026

Apr 15, 2026

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference - National Today

Apr 15, 2026

Apr 14, 2026

Savara reports 2025 results, advances MOLBREEVI toward approval - MSN

Apr 14, 2026

Apr 14, 2026

Savara to present molgramostim data at ATS conference in May By Investing.com - Investing.com Australia

Apr 14, 2026

Apr 10, 2026

Savara Inc. (NASDAQ: SVRA) proxy: MOLBREEVI FDA date, equity and vote items - Stock Titan

Apr 10, 2026

Apr 10, 2026

Aug PreEarnings: Why is Savara Inc stock going downInsider Buying & Daily Stock Momentum Reports - baoquankhu1.vn

Apr 10, 2026

Apr 10, 2026

Savara advances MOLBREEVI reviews in US., Europe, UK - MSN

Apr 10, 2026

Apr 10, 2026

Savara Advances MOLBREEVI Reviews in U.S., Europe, U.K. - MyChesCo

Apr 10, 2026

Apr 09, 2026

Street Watch: Can Savara Inc withstand a market correctionShare Buyback & Growth Oriented Trading Recommendations - baoquankhu1.vn

Apr 09, 2026

Apr 09, 2026

Savara (SVRA) Is Up 6.5% After Multi-Region Accelerated Reviews Granted for MOLBREEVI Therapy - simplywall.st

Apr 09, 2026

Apr 07, 2026

Savara (SVRA) Advances with Regulatory Reviews for Molbreevi - GuruFocus

Apr 07, 2026

Apr 07, 2026

Savara announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted the Molbreevi* marketing authorisation application (MAA) for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) - marketscreener.com

Apr 07, 2026

Apr 07, 2026

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire

Apr 07, 2026

Apr 03, 2026

SVRA Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 03, 2026

Apr 02, 2026

Savara Inc. (SVRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Apr 02, 2026

Apr 02, 2026

SVRA Stock Price, Quote & Chart | SAVARA INC (NASDAQ:SVRA) - ChartMill

Apr 02, 2026

Apr 01, 2026

Why Savara (SVRA) Is Up 5.7% After EMA Validates MOLBREEVI Application And FDA Priority Review - simplywall.st

Apr 01, 2026

Apr 01, 2026

Guggenheim Keeps Their Buy Rating on Savara (SVRA) - The Globe and Mail

Apr 01, 2026

Mar 31, 2026

Citizens reiterates Savara stock rating on regulatory progress By Investing.com - Investing.com Australia

Mar 31, 2026

Mar 31, 2026

Citizens reiterates Savara stock rating on regulatory progress - Investing.com

Mar 31, 2026

Mar 31, 2026

EMA validates Savara’s MOLBREEVI application for autoimmune PAP By Investing.com - Investing.com South Africa

Mar 31, 2026

Mar 30, 2026

Savara (SVRA) MAA Submission in Europe Receives Validation - GuruFocus

Mar 30, 2026

Mar 30, 2026

Jefferies reiterates Savara stock Buy rating on approval confidence By Investing.com - Investing.com India

Mar 30, 2026

Mar 30, 2026

Jefferies sees Savara stock approval odds at 90% for rare lung drug - Investing.com Canada

Mar 30, 2026

Mar 30, 2026

Jefferies reiterates Savara stock Buy rating on approval confidence - Investing.com UK

Mar 30, 2026

Mar 30, 2026

Jefferies sees Savara stock approval odds at 90% for rare lung drug By Investing.com - Investing.com South Africa

Mar 30, 2026

Mar 30, 2026

Savara : Corporate Presentation - marketscreener.com

Mar 30, 2026

Mar 30, 2026

Savara Inc announced that its Marketing Authorization Application (MAA) for Molbreevi*, a treatment for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), has been formally validated by the European Medicines Agency (EMA). - Bitget

Mar 30, 2026

Mar 30, 2026

EMA validates Savara’s MOLBREEVI application for autoimmune PAP - Investing.com

Mar 30, 2026

Mar 30, 2026

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire

Mar 30, 2026

Mar 27, 2026

Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com

Mar 27, 2026

Mar 27, 2026

Savara grants inducement equity awards to new employee - MSN

Mar 27, 2026

Mar 26, 2026

Death Cross: Whats the fair value of Savara Inc stockTrade Risk Report & Low Risk Entry Point Tips - baoquankhu1.vn

Mar 26, 2026

Mar 26, 2026

High Growth Tech Stocks To Watch In The US March 2026 - Sahm

Mar 26, 2026

Mar 24, 2026

Savara (SVRA) to Release Earnings on Tuesday - MarketBeat

Mar 24, 2026